GLPwatch
Treatment of Type 2 Diabetes in Patients with Obesity: A Review.
Endocrinol Metab Clin North Am · 2025
Last updated 2026-05-28Weekly injectable incretin drugs for type 2 diabetes and obesity improved blood sugar control, weight, and reduced major heart-related events in studies. Bariatric surgery provided the most lasting benefits for people with both conditions who did not meet goals with medication and lifestyle changes alone.
AI summary of the abstract below.
| Journal | Endocrinol Metab Clin North Am, 2025 |
|---|---|
| Citations | 4 |
| Molecules | — |
| Conditions studied | Type 2 Diabetes, Obesity |
Abstract
Type 2 diabetes and obesity have some overlapping pathophysiology. This has allowed for the creation of therapies which are highly effective in treating both conditions. Weekly subcutaneous incretin agonists are preferred agents as they provide significant improvement in glycemic parameters, weight, and other comorbidities, like heart failure and reduce major adverse cardiovascular event. Bariatric surgery continues to show the most durable benefits for patients with both type 2 diabetes mellitus and obesity and should be considered in patients who are unable to meet goals with pharmacotherapy and lifestyle.
Verbatim abstract via PubMed 39919872 ↗